Replies to post #157231 on Biotech Values

[pollyvonwog]

My point is that what makes he think amrn IP is weak when Pronova actually won their suit against Par/Teva. Has he done any DD and compared Lovaza patents vs Vascepa's ?

No clue! DD will have to answer that one :)

I've only looked into AMRN a little bit, but my sense is that AMRN and the challengers would settle before it actually goes to court.

On another note, as long as FDA hasn't issued on NCE, other companies cant file paragraph IVs, correct?

[jq1234]

Even though GSK won against Teva/Par, they at least hedged by settling with Apotex which will allow generic Lovaza on the market 2 years before the second patent expires in 2017.